deltatrials
Completed PHASE2 NCT00033267

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Mantle Cell Lymphoma
Interventions temsirolimus
Updated 6 times since 2017 Last updated: Apr 2, 2014 Started: Apr 30, 2002 Primary completion: Feb 28, 2006 Completion: Feb 29, 2008

This PHASE2 trial investigates Recurrent Mantle Cell Lymphoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States